62673-69-2 Usage
Description
GSK-3β Inhibitor VI is a thienyl-chloromethyl ketone compound that acts as a cell-permeable, irreversible, and non-ATP competitive inhibitor of glycogen synthase kinase-3 beta (GSK-3β). It is a promising pharmaceutical candidate for various applications due to its ability to inhibit the activity of GSK-3β, a key enzyme involved in numerous cellular processes.
Uses
Used in Pharmaceutical Industry:
GSK-3β Inhibitor VI is used as a research tool for studying the role of GSK-3β in various cellular processes and diseases. It helps researchers understand the molecular mechanisms underlying the regulation of GSK-3β and its potential as a therapeutic target for various conditions.
Used in Neurodegenerative Disease Research:
GSK-3β Inhibitor VI is used as a potential therapeutic agent for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Inhibition of GSK-3β has been shown to protect neurons from degeneration and reduce the accumulation of toxic protein aggregates, which are hallmarks of these diseases.
Used in Cancer Research:
GSK-3β Inhibitor VI is used as a potential anticancer agent, as GSK-3β has been implicated in the regulation of cell cycle progression, apoptosis, and tumorigenesis. Inhibition of GSK-3β may help prevent the uncontrolled cell growth and division associated with cancer.
Used in Diabetes Research:
GSK-3β Inhibitor VI is used as a potential therapeutic agent for diabetes, as GSK-3β plays a role in the regulation of insulin signaling and glucose homeostasis. Inhibition of GSK-3β may help improve insulin sensitivity and glucose tolerance in diabetic patients.
Used in Drug Discovery:
GSK-3β Inhibitor VI serves as a lead compound for the development of novel GSK-3β inhibitors with improved potency, selectivity, and pharmacokinetic properties. These inhibitors may have potential applications in the treatment of various diseases and conditions where GSK-3β plays a critical role.
Check Digit Verification of cas no
The CAS Registry Mumber 62673-69-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,6,7 and 3 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 62673-69:
(7*6)+(6*2)+(5*6)+(4*7)+(3*3)+(2*6)+(1*9)=142
142 % 10 = 2
So 62673-69-2 is a valid CAS Registry Number.
62673-69-2Relevant articles and documents
Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools
Perez, Daniel I.,Conde, Santiago,Perez, Concepcion,Gil, Carmen,Simon, Diana,Wandosell, Francisco,Moreno, Francisco J.,Gelpi, Jose L.,Luque, Francisco J.,Martinez, Ana
scheme or table, p. 6914 - 6925 (2010/02/28)
Thienylhalomethylketones, whose chemical, biological, and pharmaceutical data are here reported, are the first irreversible inhibitors of GSK-3β described to date. Their inhibitory activity is likely related to the cysteine residue present in the ATP-binding site, which is proposed as a relevant residue for modulation of GSK-3 activity. The good cell permeability of the compounds allows them to be used in different cell models. Overall, the results presented here support the potential use of halomethylketones as pharmacological tools for the study of GSK-3β functions and suggest a new mechanism for GSK-3β inhibition that may be considered for further drug design.
Bromothiophene Reactions. I. Friedel-Crafts Acylation
Agua, M. J. del,Alvarez-Insua, A. S.,Conde, S.
, p. 1345 - 1347 (2007/10/02)
Friedel-Crafts acylation of 2,5-dibromo- and 2,3,5-tribromothiophenes with different acyl chlorides and anhydrous aluminium trichloride has been studied.The reaction afforded a mixture of acyl derivatives and tetrabromothiophene.The results obtained suggest a mechanism which involves the formation of bromine cations in the reaction medium.Several products obtained in this reaction are described.
